An experimental drug called, veliparib, is being studied for treatment of patients with squamous NSCLC. This drug is a "PARP" inhibitor and may be used with chemotherapy or radiation to help improve efficacy. Although it's too early to tell if this drug will be FDA-approved, the possibility of having another treatment option is exciting news. A press release can be found here: biospace.com/News/abbvie-re...
FDA grants orphan drug status to an ex... - Lung Cancer Support
FDA grants orphan drug status to an experimental drug for squamous NSCLC
Written by
MFH_Advocate
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
FDA approval for Investigational drug Small Cell Lung Cancer
Hello all,
FDA approved APG-1252 as a investigational drug for treatment for small cell on or about...
FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression
On May 18th, 2020, the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the...
First Targeted Adjuvant Therapy for EGFR Non Small Cell Lung Cancer (stage IB-IIIA)
On December 18th, 2020, the Food and Drug Administration (FDA) approved Tagrisso (osimertinib) for...
Update
Well I got my results yesterday, not what I was hoping for. Cancer is still growing although at a...
An immunotherapy now approved for first-line treatment
Late yesterday, the FDA approved Keytruda (an immunotherapy) as a first-line treatment for patients...
Pet Scan results are back
To be, or not to be...NED. That is the question -William Shakespeare and me 😂
